Adalimumab biosimilar (Alteogen/Cristalia)

阿达木单抗生物类似药 (Alteogen/Cristalia)

Report date: 2025/05/06 15:48:45

Base Information

Drug NameAdalimumab biosimilar (Alteogen/Cristalia)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAlteogen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAlteogen Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune Diseases

ATC CodeN/A